These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 21807512)
1. Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. Goreshnik I; Brock AM; Maly DJ Bioorg Med Chem Lett; 2011 Sep; 21(17):4951-5. PubMed ID: 21807512 [TBL] [Abstract][Full Text] [Related]
2. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577 [TBL] [Abstract][Full Text] [Related]
3. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein. Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970 [TBL] [Abstract][Full Text] [Related]
4. Bcl-2 family proteins as targets for anticancer drug design. Huang Z Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648 [TBL] [Abstract][Full Text] [Related]
5. Molecular docking studies of anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides from Panax ginseng. Sathishkumar N; Sathiyamoorthy S; Ramya M; Yang DU; Lee HN; Yang DC J Enzyme Inhib Med Chem; 2012 Oct; 27(5):685-92. PubMed ID: 21919598 [TBL] [Abstract][Full Text] [Related]
6. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Muchmore SW; Sattler M; Liang H; Meadows RP; Harlan JE; Yoon HS; Nettesheim D; Chang BS; Thompson CB; Wong SL; Ng SL; Fesik SW Nature; 1996 May; 381(6580):335-41. PubMed ID: 8692274 [TBL] [Abstract][Full Text] [Related]
7. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
8. Characterization and expression analyses of anti-apoptotic Bcl-2-like genes NR-13, Mcl-1, Bcl-X1, and Bcl-X2 in Atlantic cod (Gadus morhua). Feng CY; Rise ML Mol Immunol; 2010 Jan; 47(4):763-84. PubMed ID: 19923001 [TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131 [TBL] [Abstract][Full Text] [Related]
10. The cell death machinery controlled by Bax and Bcl-XL is evolutionarily conserved in Ciona intestinalis. Takada N; Yamaguchi H; Shida K; Terajima D; Satou Y; Kasuya A; Satoh N; Satake M; Wang HG Apoptosis; 2005 Dec; 10(6):1211-20. PubMed ID: 16215691 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451 [TBL] [Abstract][Full Text] [Related]
12. Bcl-2 family interactome analysis using bacterial surface display. Zhang S; Link AJ Integr Biol (Camb); 2011 Aug; 3(8):823-31. PubMed ID: 21713285 [TBL] [Abstract][Full Text] [Related]
13. Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis. Han J; Modha D; White E Oncogene; 1998 Dec; 17(23):2993-3005. PubMed ID: 9881701 [TBL] [Abstract][Full Text] [Related]
14. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Hossini AM; Geilen CC; Fecker LF; Daniel PT; Eberle J Oncogene; 2006 Apr; 25(15):2160-9. PubMed ID: 16288206 [TBL] [Abstract][Full Text] [Related]
15. Bax-independent inhibition of apoptosis by Bcl-XL. Cheng EH; Levine B; Boise LH; Thompson CB; Hardwick JM Nature; 1996 Feb; 379(6565):554-6. PubMed ID: 8596636 [TBL] [Abstract][Full Text] [Related]
16. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Krajewska M; Moss SF; Krajewski S; Song K; Holt PR; Reed JC Cancer Res; 1996 May; 56(10):2422-7. PubMed ID: 8625322 [TBL] [Abstract][Full Text] [Related]
17. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. Dutta S; Ryan J; Chen TS; Kougentakis C; Letai A; Keating AE J Mol Biol; 2015 Mar; 427(6 Pt B):1241-1253. PubMed ID: 25451027 [TBL] [Abstract][Full Text] [Related]
18. Identification of core structural residues in the sequentially diverse and structurally homologous Bcl-2 family of proteins. Lama D; Sankararamakrishnan R Biochemistry; 2010 Mar; 49(11):2574-84. PubMed ID: 20141168 [TBL] [Abstract][Full Text] [Related]
19. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein. Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891 [TBL] [Abstract][Full Text] [Related]